At the news
? NEUTRALIMPACT 4/10 8-K filed Aug 17, 2026 at 09:05 ET
KKR Genetic Disorder L.P. is selling 5,000,000 shares of BridgeBio common stock at $78.00 per share in an underwritten secondary offering. BridgeBio receives no proceeds, but the transaction diversifies its shareholder base and removes a large overhang from a major institutional holder. The offering is expected to close on August 17, 2026, with a 30-day lock-up on the selling stockholder.
- KKR Genetic Disorder L.P. is selling 5,000,000 shares of BBIO common stock at $78.00 per share.
- BridgeBio will not receive any proceeds from the offering.
- The offering is oversubscribed and priced at $78.00 per share, with underwriters paying $77.415 per share.
- Underwriters include William Blair, Goldman Sachs, and KKR Capital Markets.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access